Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neovasculgen for Peripheral Nerve Injury
NCT02352649Phase 2Unknown
- Sponsor
- Artgen Biotech
- Start
- Apr 2015
- Primary completion
- Mar 2016
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
01
Overview
Phase 2, randomised, double-blind trial of neovasculgen in peripheral nerve injury (PNI) (3 arms), sponsored by Artgen Biotech. Primary endpoints: Disabilities of the Arm, Shoulder and Hand Measure at 540 days and Adverse events at 540 days. Status: unknown.
02
Drugs
neovasculgen
03
Conditions
peripheral nerve injury (PNI)
Beyond the preview
Go deeper on NCT02352649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02352649.